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ABSTRACT
Objectives: Most patients with anti-NMDA receptor (NMDAR) encephalitis have intrathecal syn-
thesis of antibodies, which cause a decrease of cell surface and synaptic NMDAR. Antibodies are
immunoglobulin G (IgG)1 and IgG3 subtypes and can potentially activate complement. We examined
whether complement immunoreactivity and antibody-secreting cells (plasma cells/plasmablasts) are
present in the brain of these patients.
Methods: Cultured rat hippocampal neurons were used in an immunocytochemical assay to test
whether patients’ antibodies can fix complement. Using the same reagents (antibodies to C9neo, C5b-9,
C3), complement immunoreactivity was determined in the brain of 5 patients, the teratoma of 21 patients,
and appropriate control tissues. A set of markers for B (CD20), T (CD3, CD4, CD8) and antibody-secreting
cells (plasma cells/plasmablasts, CD138) were used to examine the brain inflammatory infiltrates.
Results: Patients’ antibodies were able to bind complement in vitro, but deposits of complement
were not detected in patients’ brain. Parallel experiments with teratomas showed that in contrast
to the brain, the neural tissue of the tumors contained complement. Analysis of the inflammatory
infiltrates in brain samples from autopsy or biopsy performed 3–4 weeks after symptom presen-
tation demonstrated numerous antibody-secreting cells (CD138) in perivascular, interstitial,
and Virchow-Robin spaces, and B and T cells predominantly located in perivascular regions.
Conclusions: Complement-mediated mechanisms do not appear to play a substantial pathogenic
role in anti-NMDAR encephalitis. In contrast, there are copious infiltrates of antibody-secreting
cells (plasma cells/plasmablasts) in the CNS of these patients. The demonstration of these cells
provides an explanation for the intrathecal synthesis of antibodies and has implications for treat-
ment. Neurology® 2011;77:589–593
GLOSSARY
BBB  blood–brain barrier; IgG  immunoglobulin G; NMDAR  NMDA receptor.
Anti-NMDA receptor (NMDAR) encephalitis is a severe but treatable disorder that results in
psychiatric, memory, and stereotyped motor symptoms, and associates with teratomas depend-
ing on patient’s age, gender, and ethnicity.1 In vitro and in vivo experiments demonstrate that
patients’ antibodies cause a selective and reversible decrease in NMDAR surface density and
synaptic localization that correlates with antibody titers and is mediated by crosslinking and
internalization of the receptors.2 The antibodies are IgG1 and IgG3 subtypes3,4 and while they
can potentially activate complement, it is unknown if this occurs in the disease. Previous
neuropathologic studies showed microglial activation, moderate inflammatory infiltrates that
predominated in perivascular spaces, deposits of IgG, and absent or rare neuronal degenera-
tion.5,6 In these studies, absence of complement and presence of plasma cells were reported but
were not extensively studied.
From the Departments of Neurology (E.M.-H., J.D.) and Pathology and Laboratory Medicine (M.M.-L.), University of Pennsylvania, Philadelphia;
Department of Neurosciences (J.H.), Clinic of Neurology, University of Geneva, Switzerland; Department of Neurology (Y.S.-M.), University of
North Carolina, Chapel Hill; and Department of Neurology (N.S.), Kaiser Permanente, Los Angeles, CA. E.M.-H. is currently with the Department
of Neurology, Hospital de Sant Pau, University Autònoma of Barcelona, Spain. J.D. is currently at Institut d’Investigació Biomèdica August Pi i
Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Spain.
References e1–e9 are available on the Neurology® Web site at www.neurology.org.
Study funding: Supported in part by RO1CA89054 and RO1CA107192 (J.D.) and Fondo de Investigaciones Sanitarias FI08/00285 (E.M.-H.).





reprint requests to Dr. Josep
Dalmau, Department of
Neurology, 3 W. Gates,
University of Pennsylvania, 3400
Spruce Street, Philadelphia, PA
19104
Josep.Dalmau@uphs.upenn.edu
Copyright © 2011 by AAN Enterprises, Inc. 589
The MRI of many patients with anti-
NMDAR encephalitis is normal or shows
mild to moderate abnormal findings which
are often transient or reversible.7,e1,e2 Moreover,
despite the severity of the disorder, 75% of
patients have full or substantial neurologic re-
covery, suggesting that complement-mediated
neuronal toxicity is unlikely to play a major
pathogenic role.7 We also postulated that the
high intrathecal synthesis of antibodies
identified in most patients1,4,e3 indicates the
presence of antibody-secreting cells in the CNS.
We report here findings that support these
hypotheses.
Figure 1 Comparative analysis of complement immunostaining in brain and tumor
Paraffin-embedded sections of brain of 2 patients with anti-NMDA receptor (NMDAR) encephalitis (A, B), control brain (C), and teratomas of patients with
anti-NMDAR encephalitis (D–F), all immunostained with anti-C9neo. While patients’ tumors show intense complement immunoreactivity on the cell surface
of neurons and neuronal processes, the brain of patients and a control individual show lack of complement (the nuclear staining is not specific). Inset in D
shows staining of neurons contained in the tumor with MAP2, a specific dendritic marker. Scale  20 m.







to brain sample Treatment Outcome
35/F/ovarian
teratoma







in medial temporal lobes







myoclonic and dyskinetic movements,





in parietal cortex; mild
leptomeningeal
enhancement
3 mo (autopsy) C Died
7/M/no
tumor
Seizures, reduction of verbal output,
orofacial and choreoathetotic
movements, mild right hemiparesis,
















5/F/no tumor Chorea, emotional lability, dysphagia,
agitation, masticatory and pelvic
thrusting, sleep and autonomic
dysfunction
OCB Normal 25 d (autopsy) C Died
59/M/no
tumor
Behavioral changes, decreased verbal
output, somnolence, neck stiffness,
myoclonic status epilepticus
94 L WBC; protein
129 mg/dL; high IgG
index; OCB; ITS
Increased FLAIR signal







Abbreviations: C  corticosteroids; CTX  cyclophosphamide; FLAIR  fluid-attenuated inversion recovery; IgG  immunoglobulin G; ITS  intrathecal
synthesis of NMDAR antibodies, calculated as ine3; IVIg  intravenous immunoglobulins; NMDAR  NMDA receptor; OCB  CSF-specific oligoclonal bands;
PLEX  plasma exchange; RTX  rituximab; WBC  white blood cells.
a For patient 4 only CSF was available. All other patients had antibodies detectable in serum and CSF.
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METHODS Patients, tissue, neuronal cultures, and in
vitro analysis of complement binding. Tissues included
paraffin-embedded brain biopsy or autopsy samples of 5 patients
with anti-NMDAR encephalitis (table), 2 brain tissue samples
from autopsies of neurologically normal individuals, 21 ovarian
teratomas of patients with anti-NMDAR encephalitis, and 8
ovarian teratomas of individuals without encephalitis and with-
out NMDAR antibodies.
Cultures of rat hippocampal neurons were established as re-
ported.e4 In vitro analysis of complement binding by patients’
antibodies is described in appendix e-1 on the Neurology Web
site at www.neurology.org.
Immunohistochemistry. Paraffin-embedded brain and tu-
mor sections were deparaffinized and the antigen retrieved as
reported.e5 Tissue sections were serially incubated with 0.3%
H2O2 for 15 minutes, 5% goat serum for 30 minutes, and pri-
mary antibodies (C3, C9neo, MAP2, CD3, CD4, CD8, CD20,
or CD138) overnight at 4°C, followed by the appropriate biotin-
ylated secondary antibodies (1:2,000) for 2 hours. Reactivity was
developed with the avidin-biotin-peroxidase method (see appen-
dix e-1 for further information).
Standard protocol approvals, registrations, and patient
consents. Studies were approved by the Institutional Review
Board of the University of Pennsylvania. In all instances, written
consent for studies was provided by guardians of patients.
RESULTS Complement immunoreactivity in the tumor
but not in the brain of patients with anti-NMDAR
encephalitis. Using cultures of rat hippocampal neu-
rons, we confirmed that patients’ antibodies were
able to fix complement (figure e-1). Next, we exam-
ined the presence of complement in patients’ brain
and tumor, comparing these tissues side by side. De-
posits of IgG in patients’ brain were reported in
previous studies5 and are not described here. No
complement immunostaining was detected in any of
the brain regions from autopsies of 3 patients (fron-
tal, temporal lateral, temporal medial/hippocampus,
and parietal) and biopsies of 2 patients with anti-
NMDAR encephalitis (figure 1, A and B), or in the
control brain samples (figure 1C).
Patient 3 was atypical because the brain MRI
showed cortical cystic lesions suggesting necrosis (figure
2). Biopsy of one of the lesions showed necrosis, dystro-
phic calcification, chronic inflammation, and microglial
activation. Studies for an infectious process were nega-
tive and the etiology of these cystic lesions remains un-
known. Complement immunostaining was only
detected in the necrotic tissue (figure 2D).
All teratomas from patients with anti-NMDAR
encephalitis and control teratomas showed the pres-
ence of nervous tissue, including neuronal-like cells
and networks of neuronal processes expressing
MAP2 (inset in figure 1D). Complement immuno-
reactivity was found in 17 of 21 teratomas of patients
with anti-NMDAR encephalitis (figure 1, D–F) and
in 5 of 8 control teratomas (not shown); the cell sur-
face complement immunoreactivity was highly con-
fined to neuronal tissue.
Antibody-secreting cells in perivascular, interstitial,
and Virchow-Robin spaces. Brain tissue samples from
patients 3–5 were available for these studies. In all 3
patients, abundant CD138 cells (plasma cells/
plasmablasts) were noted in perivascular regions and
interstitial space (figures 3 and e-2). In perivascular
regions, the CD138 cells were part of B- and T-cell
lymphocytic cuffing surrounding blood vessels. In
Virchow-Robin spaces, CD138 cells were found
along with other inflammatory infiltrates lining the
meningeal-brain surface in proximity to the CSF
(figure 3K).
DISCUSSION The 2 main findings of this study are
the absence of deposits of complement and the
presence of abundant CD138 cells (plasma cells/
Figure 2 Brain MRI and biopsy of a patient with anti-NMDA receptor (NMDAR)
encephalitis and cortical cystic lesions
Fluid-attenuated inversion recovery MRI obtained at 2 (A), 8 (B), and 16 (C) weeks after
symptom presentation. There is progressive development of abnormal areas with cystic
changes. Biopsy of one of these lesions showed prominent necrosis, and complement immu-
nostaining in the necrotic tissue without recognizable neurons (D, immunostained with anti-
C9neo). No complement immunoreactivity was noted outside the necrotic tissue (not
shown). Scale  20 m.
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plasmablasts) in the brain of patients with anti-
NMDAR encephalitis. The absence of complement
was emphasized in studies comparing in parallel
brain and tumor tissue, showing that in contrast to
brain, the neural tissue contained in tumors frequently
had complement immunoreactivity. Whether the cys-
tic lesions in the brain of patient 3 were caused by
complement-mediated toxicity is unclear; we have
not identified similar lesions in 400 patients with
anti-NMDAR encephalitis.1
Complement immunoreactivity was identified in
81% of teratomas from patients with anti-NMDAR
encephalitis and 62.5% of teratomas from control
individuals, suggesting the presence of antibody-
dependent and independent mechanisms of comple-
ment binding. Indeed, studies using human fetal
neurons have shown spontaneous complement activa-
tion through the classic pathway in immunoglobulin-
deficient serum.8 Similar to these experiments, we
found linear deposits of complement in 5% of cultured
rodent neurons treated with human complement re-
gardless of the presence of neuronal antibody binding
(data not shown).
CD138 is a highly specific marker of plasma cells
and plasmablasts, which are precursors of plasma
cells. Our studies do not clarify whether the brain-
infiltrating CD138 cells were plasma cells or plas-
mablasts, but both types of cells are known to secrete
high amounts of antibodies.e6 These cells were found
in perivascular, interstitial, and Virchow-Robin
spaces, providing an explanation for the intrathecal
synthesis of antibodies frequently noted in anti-
NMDAR encephalitis.1,4
We postulate that after systemic immune activa-
tion by an NMDAR-expressing tumor or unknown
mechanisms, antibodies synthesized systemically may
cross the blood–brain barrier (BBB) through leaky
regions, but activated B cells that are able to cross an
intact BBB reach the brain and differentiate into
plasmablasts/plasma cells, producing most of the an-
Figure 3 CD138 cells in brain of patients with anti-NMDA receptor (NMDAR) encephalitis
Paraffin-embedded sections of brain biopsy of 2 patients with anti-NMDAR encephalitis (patient 5, top and middle rows; patient 3, lower row) immuno-
stained with anti-CD20 (A, F), anti-CD3 (B, G), anti-CD4 (C, H), anti-CD8 (D, I), and anti-CD138 (E, J–L). CD138 cells (plasma cells/plasmablasts) are
present in perivascular (E, J), Virchow-Robin (K), and interstitial spaces (L). In Virchow-Robin spaces (K), the CD138 cells are in perivascular regions
(arrows) and along the tissue surface (arrowheads) that delineates spaces containing CSF and small vessels (v). The plasma cells/plasmablasts indicated
with arrows are amplified in the inset in K. Scales  20 m.
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tibodies detected in patients’ CNS. These antibodies
cause a decrease of cell surface and synaptic
NMDAR, as reported.2 The lack of complement im-
munoreactivity in patients’ brain is likely due to the
low levels of complement in the CNS (estimated 440
times lower than serum levels9).
The brain infiltrates of plasma cells/plasmablasts
provide a plausible explanation for the prolonged
clinical course of anti-NMDAR encephalitis,1,4 and
for the limited response to plasma exchange or IVIg
once the peripheral immune response has expanded
in the CNS. Accordingly, patients with protracted
symptoms usually have persistent levels of antibodies
in the CSF.e7 The half-life of human plasmablasts is
believed to be several days, but plasma cells may live
many months in an inflammatory environment, such
as that provided by B and T cells.e6,e8,e9 Moreover,
plasma cells and most plasmablasts do not express
CD20, the target of rituximab. This is important be-
cause in current practice, patients who do not im-
prove with IV immunoglobulin, plasma exchange, or
corticosteroids are frequently treated with rituximab
or cyclophosphamide. These drugs have limited BBB
penetration but result in improvement in approxi-
mately 70% of those cases.1 While rituximab causes a
decrease of B cells and prevents maturation into
antibody-secreting cells,10 cyclophosphamide reduces
all types of inflammatory infiltrates. The distribution
of plasma cells/plasmablasts noted in this study sug-
gests that treatment strategies that facilitate BBB
penetration, such as high-dose methotrexate, may be
useful in patients with refractory symptoms and per-
sistently elevated CSF antibody titers.
Future studies should focus on the analysis of a
possibly CNS compartmentalized B cell immune re-
sponse in patients with anti-NMDAR encephalitis,
and how an expansion or retraction of this response
may explain maintenance, improvement, or relapse
of symptoms.
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